Vial

INDIVIDUAL TEST 987

pTau-181 (phospho Tau 181)

Indication

Alzheimer's disease, memory examination 

Method

SIMOA (single molecule array), tested in EDTA-plasma. 

Result

The result is reported as ng/L.  

Interpretation

Plasma pTau-181 ≥ 4.0 pg/ml support further investigations when Alzheimer's disease is suspected. The cut-off represents 99th-percentile of 150 healthy individuals. 

The result should be combined with other investigations as well as clinical symptoms for the final diagnosis. 

References 

  • Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-344.
  • Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433.  
  • Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology, and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26(3):379-386.   
  • Liu, Huei-Chun et al. Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. Dementia and geriatric cognitive disorders. Extra vol. 10,1 46-55. 26 Mar. 2020, 
  • Elisabeth H T et al., Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021 Sep;20(9):739-752. 
  • Antoinette O’Connor et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study. Molecular Psychiatry volume 26, pages5967–5976 (2021) 

More information

Learn more about sampling.
> Read more

Download request forms

Neurology

Can't find what you're looking for? We are here to help

Vial

ENSKILD ANALYS 987

pTau-181 (fosfo Tau 181)

Indikation

Alzheimers sjukdom, minnesutredning. 

Metod

SIMOA (single molecule array), analys utförs i EDTA-plasma.  

Svar

Resultat rapporteras som ng/L.  

Tolkning

Plasma pTau-181 ≥ 4.0 pg/ml motiverar vidare utredning vid misstanke om Alzheimers sjukdom. Referensvärdet representerar 99:e percentilen av 150 friska individer.  

Diagnosen baseras även på kliniska symtom och andra undersökningsfynd. 

Referenser 

  • Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-344.
  • Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433.  
  • Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology, and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26(3):379-386.   
  • Liu, Huei-Chun et al. Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. Dementia and geriatric cognitive disorders. Extra vol. 10,1 46-55. 26 Mar. 2020, 
  • Elisabeth H T et al., Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021 Sep;20(9):739-752. 
  • Antoinette O’Connor et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study. Molecular Psychiatry volume 26, pages5967–5976 (2021) 

Mer information

Mer information om provtagning.
> Läs mer

Ladda ner remiss

Neurologi

Hittar du inte vad du söker? Vi kan hjälpa till